Novel Therapies and Targets for Parkinson’s Disease

In this editorial, the authors highlight newly licensed medications for the symptomatic treatment of Parkinson’s disease (PD) and their role in the current management of PD. Non-motor symptoms (NMS), which cause significant disability in this patient group, are highlighted to emphasize their importance as targets for treatment, both in current and in future research. The clinical trial pipeline for disease-modifying treatments for PD is discussed with an emphasis on therapies targeting α-synuclein propagation and aggregation within the central nervous system. Newly licensed treatments and advances in the management of motor complications are discussed. Finally, the current state of clinical trial design is highlighted, with a focus on how study design is evolving and the potential implications for both the treatment and prevention of PD.